The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
51st Annual Meeting of the EBMT congress coverage: Lymphoma (Part 2)
Stay up to date with the latest developments in lymphoma (Part 2) with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 –April 2, 2025, Florence, Italy.
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Charalampia Kyriakou from @uclh discussed results from the study on stem cell transplantation for Waldenstrom’s Macroglobulinemia conducted by the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
ASCT in… pic.twitter.com/j4vBd96t2q
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Bertram Glass @BuchHelios presented on ctDNA as an early outcome predictor in second-line LBCL after liso-cel vs SOC. Significantly more patients achieved undetectable ctDNA with liso-cel (62%) compared to SOC (38%). In the liso-cel arm,… pic.twitter.com/8OgSpBdlOj
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Ali Bazarbachi @AUBMC_Official discusses the importance of allo-HCT in Hodgkin #lymphoma.
Follow our live feed for more updates: https://t.co/fJoKaNsrCt#lymphoma #lymsm #MedicalCongress @TheEBMT pic.twitter.com/Q2monJluFy
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Philipp Berning @UK_Muenster discussed the role of allotransplant in T-cell #lymphoma focusing on the timing of allo-HCT, how to improve outcomes, and the impact of histology on transplant outcomes.
Follow our live feed for more updates:… pic.twitter.com/2F20cArqRj
CONGRESS | #EBMT25 | PRESENTATION @DrBastosOreiroM, Gregorio Marañón Hospital provides an overview of CAR T-cell therapies in #lymphoma by sharing the clinical and real-world data in patients with DLBCL, FL, and MCL.
— Lymphoma Hub (@lymphomahub) April 1, 2025
Follow our live feed for more updates:… pic.twitter.com/LUCsEdNj3e
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) March 31, 2025
Jia Wei, Tongji Hospital, China presents interim findings from a phase I/II trial of CD19/20 CAR T-cell therapy in patients with relapsed/refractory B-cell lymphoma (N = 51). At 3 months, best ORR = 84% and CR = 52%. Patients treated with autologous… pic.twitter.com/DCHQ2HRvPY
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) March 31, 2025
Gabriele Facchin, University Hospital, Azienda sanitaria universitaria Friuli Centrale, Italy shares findings from a retrospective study in patients with relapsed/refractory lymphoma (N = 6) treated with bispecific antibodies followed by allogeneic… pic.twitter.com/ZFGBBhGPYj
CONGRESS | #EBMT25 @theEBMT | PRESENTATION @GunjanLShah @uclh presented the initial results from the phase II LUMINICE-203 study of acimtamig combined with off-the-shelf allogeneic natural killer cells (AB-101) in patients with R/R classical Hodgkin #lymphoma.
— Lymphoma Hub (@lymphomahub) March 31, 2025
N=22, ORR=86%,… pic.twitter.com/6q6QAD9kjM
CONGRESS | #EBMT25 @theEBMT | PRESENTATION
— Lymphoma Hub (@lymphomahub) March 31, 2025
Charalampia Kyriakou from @uclh discussed classification of lymphomas in the EBMT registry based on the 5th edition of the World Health Organization's classification of haematolymphoid tumors. Follow our live feed for more updates:… pic.twitter.com/fBowGkW26u
CONGRESS | #EBMT25 @theEBMT | PRESENTATION @corradini_paolo, University of Milano, discusses the role of liquid biopsy in T-cell directing treatments for lymphomas by sharing an overview of general concepts on liquid biopsy, cell free DNA, ctDNA. Importance of molecular… pic.twitter.com/PWcDuq2ddF
— Lymphoma Hub (@lymphomahub) March 31, 2025
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
